<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00151918</url>
  </required_header>
  <id_info>
    <org_study_id>SPD405-310</org_study_id>
    <secondary_id>2004-001608-11</secondary_id>
    <nct_id>NCT00151918</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease</brief_title>
  <official_title>A Multi-Centre, Open Label, Randomized, Parallel Group Pilot Study to Assess the Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess phosphate reduction and control in patients with End&#xD;
      Stage Renal Disease treated with either lanthanum carbonate or sevelamer hydrochloride&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 7, 2005</start_date>
  <completion_date type="Actual">August 22, 2005</completion_date>
  <primary_completion_date type="Actual">August 22, 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean pre-dialysis serum phosphate level</measure>
    <time_frame>The last 4 weeks of the treatment period (Weeks 5, 6, 7, &amp; 8)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean pre-dialysis serum calcium product</measure>
    <time_frame>The last 4 weeks of the treatment period (Weeks 5, 6, 7, &amp; 8)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean pre-dialysis calcium-phosphate product</measure>
    <time_frame>The last 4 weeks of the treatment period (Weeks 5, 6, 7, &amp; 8)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average daily pill burden</measure>
    <time_frame>Daily throughout for the 8 week Evaluation for Dose Adjustment Period up to the End of Study/ Withdrawal Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment emergent adverse events</measure>
    <time_frame>Throughout the study period of approximately 7.5 months.</time_frame>
    <description>Treatment-emergent adverse events (TEAEs) were defined as AEs that had an onset date and time on or after the date and time of the first dose of study medication.</description>
  </secondary_outcome>
  <enrollment>48</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanthanum carbonate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients receiving haemodialysis for ESRD&#xD;
&#xD;
          -  Patients must have received haemodialysis for chronic renal failure three times per&#xD;
             week for at least the previous 2 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Patients with clinically significant uncontrolled concurrent illness, a&#xD;
             life-threatening malignancy or current multiple myeloma&#xD;
&#xD;
          -  Patients who are HIV+&#xD;
&#xD;
          -  Patients with any significant bowel obstruction, active inflammatory bowel disease, GI&#xD;
             motility disorders, or a history of major GI surgery within the last 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2005</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

